HEALTH TECHNOLOGY

SWORD HEALTH LAUNCHES A NEW BRAND THAT EMBODIES ITS VISION TO FREE THE WORLD FROM PAIN

SWORD Health | July 05, 2022 | Read time : 1 min

SWORD HEALTH

Sword Health, the fastest growing digital musculoskeletal (MSK) solution on the market, announced that it is launching a new brand that reflects its  mission to free 2 billion people from pain. This change comes at an immense time of progress for the company as it sets its sights on growth in 2023.

The new brand position is communicated through a redesigned institutional as well as a modernized logomark composed of two circular shapes representing the company’s focus  on every member’s unique journey to a healthier life – the outlined circle represents prevention, and the filled circle treatment. The company will also be softening the look and feel of its digital applications, including the digital therapist and member app. Additionally, its color palette, iconography, photography, member experience, and apparel have all undergone a strategic upgrade to reflect the evolution of Sword Health.   

"We are announcing the beginning of a global movement to free the world from pain. It's more than just a new look and feel to us, it's the culmination of years of research and development, aimed at supporting the core goal of healing people’s pain. We're confident this movement expresses both the transformation of our company as a whole and the future of a pain-free world."

Virgilio Bento, Founder and CEO of SWORD Health

Sword Health believes in the power of people to recover at home, without resorting to surgeries or opioids. Since launching in 2015, Sword Health has worked with insurers, health systems and employers worldwide to make high quality physical care accessible to everyone. Sword Health is setting a new standard for clinical outcomes: the company’s results are of a higher quality than the traditional model, and it is delivering real cost savings to their customers while helping their employees heal quickly and safely.

About Sword Health

Sword Health is the world’s fastest growing digital musculoskeletal (MSK) care provider, on a mission to free 2 billion people from acute, chronic, and post-surgical pain. It is the first digital solution to pair its members with a licensed physical therapist and the Sword Health Digital Therapist, to deliver a clinically-proven, personalized treatment plan that is more effective, easier, and less expensive than the traditional gold standard of care. Sword Health believes in the power of people to recover at home, without resorting to imaging, surgeries or opioids. With the preventative care delivered through Sword+, it is the industry's only end-to-end digital MSK solution. Since launching in 2015, Sword Health has worked with insurers, health systems, and employers in the U.S., Canada, Europe, and Australia to make high quality musculoskeletal care accessible to everyone. 

Spotlight

In our last healthcare industry report, we looked at Healthcare’s Location Data Crisis. Our analysis of more than 15,000 facility and physician online listings showed that 48% of healthcare listings contained basic address errors that could misdirect patients. Even more problematic was the fact that 32% of facilities and physicians lacked an online local listing altogether - that’s 3.6x greater than the unlisted average 8.68% of other businesses. For this report, we followed up our analysis of the industry’s patient-facing data crisis with an exploration of the online patient journey.

Spotlight

In our last healthcare industry report, we looked at Healthcare’s Location Data Crisis. Our analysis of more than 15,000 facility and physician online listings showed that 48% of healthcare listings contained basic address errors that could misdirect patients. Even more problematic was the fact that 32% of facilities and physicians lacked an online local listing altogether - that’s 3.6x greater than the unlisted average 8.68% of other businesses. For this report, we followed up our analysis of the industry’s patient-facing data crisis with an exploration of the online patient journey.

Related News

HEALTHTECH SECURITY

BeeKeeperAI Applies Sightless Computing Technology to Pediatric Rare Disease Project

BeeKeeperAI and Novartis Biome | October 20, 2022

BeeKeeperAI, the pioneer in sightless computing on protected data, announced that it worked with scientists from Novartis Biome’s Evidence Lab and the University of California, San Francisco to train and validate an algorithm to predict instances of a rare childhood condition using real patient data from health records. This project marks the first time that confidential computing technology has been leveraged to support sightless computation by an algorithm against protected health information. “This project is an important milestone in the development of the rare disease solution by the Evidence Lab,” said Robin Roberts, Co-founder and Chief Operating Officer at Novartis Biome. “Rare diseases are often challenging to diagnose and if left untreated, they can significantly diminish a patient’s quality of life. With BeeKeeperAI, our scientists were able to securely access a large gold standard dataset that enabled us to improve the predictive capabilities of our algorithm, bringing us much closer to identifying patients early in the disease course and to improving their outcomes.” The Novartis Biome Evidence Lab was developed in collaboration with health systems and data providers as a space for health tech companies to test their digital solutions and identify ways to optimize and scale their offerings. BeeKeeperAI’s zero trust architecture supports sightless computing of algorithms against protected information. It uses advanced encryption within secure computing enclaves to enable data stewards and algorithm developers to collaborate without exposing the data or revealing important IP. The platform eliminates reliance on data deidentification or difficult to enforce contractual agreements that typically govern access to protected health information. “The traditional mechanisms for securing permission to use confidential patient information to develop healthcare AI are time-consuming and costly and that has slowed the pace of innovation in the field. We developed our platform with an eye towards addressing the constraints of existing approaches for accessing protected information and helping algorithm developers and data stewards collaborate far more effectively,” Michael Blum, MD, Co-founder and Chief Executive Officer at BeeKeeperAI The Novartis project leveraged Microsoft Azure’s confidential computing environment utilizing an Intel SGX secure enclave. Prior to moving the data into the secure enclave at UCSF, BeeKeeperAI worked with clinical and data science experts at UCSF to curate, harmonize, and encrypt data that included 28 pediatric patients diagnosed with the pediatric rare disease in question and an additional 2,000 matched controls. Simultaneously, BeeKeeperAI enabled the Novartis scientists to prepare the algorithm for the secure environment, including encrypting and uploading it to the BeeKeeperAI cloud platform. Encrypting both the data and the algorithm ensured that they remain protected throughout the computing process. Once the encrypted algorithm and data were in the secure enclave, they were decrypted, and the algorithm was allowed to compute against the identifiable data. The process was fully automated and sightless. The output of the computation was a report that provided performance metrics. Novartis scientists used the feedback from the BeeKeeperAI platform to fine-tune the algorithm and rerun it against the data. Through this iterative loop, they significantly improved the predictive capabilities of their solution to detect patients with the rare condition. The solution is now ready for further validation at additional academic medical centers known for treating this rare condition. BeeKeeperAI will be participating in the Novartis Biome's "Closing the Digital Divide: Validation through Partnership" event on Wednesday, October 19, where they will share more details of the healthcare AI project with Novartis Biome and UCSF. About Novartis Biome Novartis Biome is a bridge to help partners become an extension of Novartis own teams, working with them as easily and productively as possible to jointly innovate and co-develop digital solutions at scale. The Biome is committed to partnering with the best in the ecosystem to combine deep scientific experience with the expertise of the tech world to develop – and crucially – scale digital solutions that improve and extend patients’ lives. About BeeKeeperAI BeeKeeperAI is the pioneer in confidential, sightless computing within a zero-trust architecture for the development and deployment of AI in healthcare and other privacy protected data. BeeKeeperAI is accelerating the broader availability of AI-powered solutions that will help to redefine the future of healthcare and commerce.

Read More

HEALTH TECHNOLOGY

FDA-approved Investigator-initiated Pre-market Clinical Trial of LAmbre™ Plus LAA Closure System Obtained Medical Insurance Coverage in the US

LifeTech Scientific Corporation | September 06, 2022

LifeTech Scientific Corporation is pleased to announce that on 30 August 2022, an FDA-approved investigator-initiated pre-market clinical trial of its proprietary LAmbre™ Plus Left Atrial Appendage (LAA) Closure System has obtained medical insurance coverage in the United States, meaning that all patient enrollment of the clinical trial will be fully covered by the USA medical insurance. This is expected to facilitate the marketing and registration process of the innovative device in the United States and provide strong clinical data to support the development of the device in the global market. The investigator-initiated pre-market clinical trial received FDA approval in March 2022. This prospective, randomized, controlled, multicenter clinical trial aims to evaluate the safety and efficacy of the implantation of LAmbre™ Plus LAA occluder in non-valvular atrial fibrillation patients with large and/or irregularly shaped appendages, as compared to oral anticoagulants. The trial is planning to enroll more than 3,000 subjects from up to 75 investigational sites in the United States and undertake more than 1,500 implantations of the LAmbre™ Plus LAA occluders at a fee. After reaching the established clinical objectives and conditions, the company will submit the marketing application of the device to the FDA. "This is a great milestone in LifeTech's international roadmap. Our LAA occluders had been successfully implanted in the United States on a basis of 'compassionate use', providing a new treatment for non-valvular atrial fibrillation patients with irregularly shaped appendages. Today, the approval for the first ever USA based investigator-initiated pre-market clinical trial and the medical insurance coverage gives us a greater confidence to further accelerate our process for providing this innovative, safe and effective stroke prevention solution to patients in the United States," Mr. Xie Yuehui, Chairman and CEO, LifeTech Scientific Corporation About the LAmbre™ Plus LAA Closure System LAmbre™ Plus LAA Closure System is independently developed by LifeTech Scientific Corporation. The device closes patient's left atrial appendage through percutaneous occlusion procedure to prevent stroke caused by detachment of thrombus from the left atrial appendage. LAmbre™ Plus LAA Closure System is a structural optimized version of the LAmbre™ LAA Closure System, which is an advanced medical device in the industry in terms of design and technology, and currently it has been widely used in over 40 countries with nearly 20,000 cases in clinical application around the world. About LifeTech Scientific Corporation Established in 1999, LifeTech Scientific Corporation (1302.HK) is committed to the R&D, manufacture, and sales of minimally invasive interventional medical devices for cardio-cerebrovascular and peripheral vascular diseases. The company has a comprehensive product portfolio in the treatment of structural heart diseases, peripheral vascular diseases, bradycardia, neurological, neoplastic and respiratory diseases, alongside a unique iron-based bioresorbable technology. To date, 14 of the company's products have been approved as innovative medical devices by the National Medical Products Administration, and with a global reach of over 100 countries and regions, the company is currently one of the few domestic companies in China with a highly internationalized business structure.

Read More

FUTURE OF HEALTHCARE

Veradigm Digital Health Media Becomes the First EHR Marketing Solution to Join the Point of Care Marketing Association

Veradigm | November 23, 2022

Veradigm, a business unit of Allscripts announced The Point of Care Marketing Association a nonprofit organization to support the continued growth of the Point of Care channel through education and advocacy, has welcomed Veradigm to its membership. Veradigm Digital Health Media is the first EHR marketing solution to be accepted as a member of POCMA Stuart Green, Senior Vice President & General Manager, Veradigm has joined POCMA’s board of directors POCMA exists to advocate for the effective use of the point of care communication channel to advance patient healthcare outcomes. Members of the nonprofit point of care industry association work closely with brand, agency, and provider stakeholders to advocate for the channel and promote its positive impact to ensure its continued growth as a vital and innovative segment of healthcare marketing. “POCMA is excited to have Veradigm as a member and the first within the EHR landscape. Veradigm’s platform of reaching HCPs in their workflow makes them an excellent resource for the association and its members. We look forward to their insights and involvement as we grow the POC industry.” POCMA Executive Director, Nicole Divinagracia “At Veradigm, we share in POCMA’s goal of raising healthcare providers’ awareness through innovative point of care marketing channels,” said Stuart Green, Senior Vice President & General Manager, Veradigm. “With our membership, we look forward to contributing to the establishment of industry best practices and building connections with other point-of-care industry leaders and influencers.” About Allscripts Allscripts is a leader in healthcare information technology solutions that advance clinical, financial and operational results. Our innovative solutions connect people, places and data across an Open, Connected Community of Health™. Connectivity empowers caregivers to make better decisions and deliver better care for healthier populations. About Veradigm® Veradigm is a healthcare technology company that drives value through its unique combination of platforms, data, expertise, connectivity, and scale. Some healthcare technology companies deliver clinical data for biopharma and health plans, some help turn that data into insights, others serve healthcare providers directly by providing point-of-care clinical software and patient outreach platforms. Veradigm does it all. The Veradigm Network features a dynamic community of solutions and partners providing advanced insights, technology, and data-driven solutions, all working together to transform healthcare insightfully.

Read More